MSPharma: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon's Biosimilar Candidate to Eylea (Aflibercept), in the MENA Region

(marketscreener.com) EQS-News: Formycon AG / Key word: Agreement MS Pharma becomes Partner for the Commercialization of FYB203, Formycon's Biosimilar Candidate to Eylea® , in the MENA Region 15.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // May 15,...https://www.marketscreener.com/quote/stock/FORMYCON-AG-7012193/news/MS-Pharma-becomes-Partner-for-the-Commercialization-of-FYB203-Formycon-s-Biosimilar-Candidate-to-Ey-46725936/?utm_medium=RSS&utm_content=20240515